These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31610066)

  • 1. Targeting Bortezomib to Bone Increases Its Bone Anabolic Activity and Reduces Systemic Adverse Effects in Mice.
    Wang H; Zhang H; Srinivasan V; Tao J; Sun W; Lin X; Wu T; Boyce BF; Ebetino FH; Boeckman RK; Xing L
    J Bone Miner Res; 2020 Feb; 35(2):343-356. PubMed ID: 31610066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.
    Tao J; Srinivasan V; Yi X; Zhao Y; Zhang H; Lin X; Zhou X; Boyce BF; Villalta PW; Ebetino FH; Ho KK; Boeckman RK; Xing L
    J Bone Miner Res; 2022 Apr; 37(4):629-642. PubMed ID: 34970782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice.
    Wang H; Xiao L; Tao J; Srinivasan V; Boyce BF; Ebetino FH; Oyajobi BO; Boeckman RK; Xing L
    Pharmaceutics; 2018 Sep; 10(3):. PubMed ID: 30201882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone-targeted bortezomib increases bone formation within Calvarial trans-sutural distraction osteogenesis.
    Chen H; Cai G; Ruan X; Lu Y; Li G; Chen Z; Guan Z; Zhang H; Sun W; Wang H
    Bone; 2023 Apr; 169():116677. PubMed ID: 36646264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Dou QP; Zonder JA
    Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma.
    Marino S; Petrusca DN; Bishop RT; Anderson JL; Sabol HM; Ashby C; Layer JH; Cesarano A; Davé UP; Perna F; Delgado-Calle J; Chirgwin JM; Roodman GD
    Haematologica; 2024 May; 109(5):1501-1513. PubMed ID: 37981834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withaferin A: a proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone.
    Khedgikar V; Kushwaha P; Gautam J; Verma A; Changkija B; Kumar A; Sharma S; Nagar GK; Singh D; Trivedi PK; Sangwan NS; Mishra PR; Trivedi R
    Cell Death Dis; 2013 Aug; 4(8):e778. PubMed ID: 23969857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
    Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
    Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxychloroquine and a low activity bisphosphonate conjugate prevent and reverse ovariectomy-induced bone loss in mice through dual antiresorptive and anabolic effects.
    Yao Z; Ayoub A; Srinivasan V; Wu J; Tang C; Duan R; Milosavljevic A; Ebetino F; Frontier A; Boyce B
    Res Sq; 2024 May; ():. PubMed ID: 38746138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
    Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
    Polzer K; Neubert K; Meister S; Frey B; Baum W; Distler JH; Gückel E; Schett G; Voll RE; Zwerina J
    Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
    Accardi F; Toscani D; Bolzoni M; Dalla Palma B; Aversa F; Giuliani N
    Biomed Res Int; 2015; 2015():172458. PubMed ID: 26579531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
    de la Puente P; Luderer MJ; Federico C; Jin A; Gilson RC; Egbulefu C; Alhallak K; Shah S; Muz B; Sun J; King J; Kohnen D; Salama NN; Achilefu S; Vij R; Azab AK
    J Control Release; 2018 Jan; 270():158-176. PubMed ID: 29196043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes.
    Stadelmann B; Aeschbacher D; Huber C; Spiliotis M; Müller J; Hemphill A
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3352. PubMed ID: 25474446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.
    Fu Y; Liu X; Zhang F; Jiang S; Liu J; Luo Y
    Cell Death Dis; 2019 Apr; 10(4):319. PubMed ID: 30967527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.
    Garcia-Gomez A; Quwaider D; Canavese M; Ocio EM; Tian Z; Blanco JF; Berger AJ; Ortiz-de-Solorzano C; Hernández-Iglesias T; Martens AC; Groen RW; Mateo-Urdiales J; Fraile S; Galarraga M; Chauhan D; San Miguel JF; Raje N; Garayoa M
    Clin Cancer Res; 2014 Mar; 20(6):1542-54. PubMed ID: 24486586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib prevents ovariectomy-induced osteoporosis in mice by inhibiting osteoclast differentiation.
    Kim SH; Kim MO; Kim HJ; Neupane S; Kim HJ; Lee JH; Kim HH; Kim JY; Lee Y
    J Bone Miner Metab; 2018 Sep; 36(5):537-546. PubMed ID: 29027021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.